Evidence map›Paper›PMID 32257821›Full record

ArticleJournal of clinical & translational endocrinology2020

Oral ethinyl estradiol treatment in women with cystic fibrosis is associated with lower bone mineral density.

Malinda Wu, William R Hunt, Melissa S Putman, Vin Tangpricha

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical & translational endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Updates in Cystic Fibrosis Bone Disease in Adults.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
    Review
  2. The endocrine complications of cystic fibrosis.Nature reviews. Endocrinology · 2026
    Review
  3. Cystic fibrosis-related bone disease: an update on screening, diagnosis, and treatment.Therapeutic advances in endocrinology and metabolism · 2025
    Review
  4. Article
  5. Article
  6. Gynecologic health care for females with cystic fibrosis.Journal of clinical & translational endocrinology · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Malinda WuDivision of Endocrinology and Metabolism, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA.
William R HuntDivision of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Melissa S PutmanDivisions of Endocrinology, Boston Children's Hospital and Massachusetts General Hospital, Boston, MA, USA.
Vin TangprichaDivision of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory University School of Medicine and the Atlanta VA Medical Center, Atlanta, GA, USA.
Emory University · USAtlanta VA Medical Center · USBoston Children's Hospital · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

objectiveThe purpose of this study was to determine whether estrogen supplementation primarily from oral contraceptive pills compared to no estrogen supplementation is associated with differences in mean bone mineral density (BMD) measured by DXA in a cross-sectional study of women with cystic fibrosis (CF).

methodsIn this cross-sectional study of women with CF followed at a single center, we analyzed 49 women with CF ages 18-50 years with a documented DXA. BMD of women with CF taking estrogen supplementation was compared to BMD of women with CF not taking estrogen supplementation.

resultsTwelve women with CF were taking estrogen supplementation with mean dose of 23.3 mcg/day (SD 6.9 mcg/day) of ethinyl estradiol. There were no statistically significant differences between demographics of the 12 women with CF taking estrogen supplementation compared to the 37 women with CF not taking estrogen supplementation. Women taking estrogen had lower mean lumbar spine Z-score: -0.7 ± 0.7, compared to women not taking estrogen, Z-score: -0.04 ± 1.0 (p-value 0.046). Women taking estrogen had lower mean BMD at the lumbar spine: 0.952 ± 0.086 g/cm

conclusionLow-dose estrogen supplementation in premenopausal women with CF was associated with lower BMD compared to no estrogen supplementation in a similar group of premenopausal young women with CF. Future studies are needed to investigate the optimal formulation, route of administration, and dose to accrue and preserve bone mass in premenopausal women with CF.

Indexed as

BMD, Bone mineral densityBMI, Body mass indexCFBD, Cystic fibrosis-related bone diseaseCF, Cystic fibrosisCFTR, Cystic fibrosis transmembrane conductance regulatorCystic fibrosis-related bone diseaseDXA, Dual X-ray absorptiometryEstrogenEthinyl estradiolFEV1, Forced expiratory volume in 1 secondFVC, Forced vital capacityHypogonadismLumbar spineOsteoporosisPOI, Primary ovarian insufficiency

Identifiers

PMID32257821
PMCPMC7109452
OpenAlexW3010643646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.